Borghi L, Elia G, Trapassi M R, Melloni E, Amato F, Barbarese F, Novarini A
Institute of Semeiotica Medica, University of Parma, Italy.
Pharmacology. 1988;36(5):348-55. doi: 10.1159/000138405.
The effects of indapamide (2.5 mg once a day) on urinary composition are reported in 20 patients (10 with recurrent calcium nephrolithiasis and 10 with essential hypertension) compared with 20 controls. Indapamide was well absorbed in every patient (mean plasma level at the steady state was 111 +/- 41 ng/ml) and its antihypertensive action was more pronounced in hypertensive than in normotensive patients. It lowered calcium excretion in 18/20 patients (mean fall on the 7th day of treatment: 53%) and raised the Mg/Ca ratio in 20/20 patients (mean increase on the 7th day: 167%). The effect on Ca2+ and Mg2+ excretion was not associated with a strong diuretic effect. During intravenous calcium loading (0.375 mmol/kg body weight) 6 normal subjects after a single oral dose of indapamide excreted less calcium, suggesting a direct renal hypocalciuric action by the drug. Indapamide could represent an alternative drug to thiazide diuretics in diseases with dangerous renal calcium losses, but long-term studies are needed.
报告了吲达帕胺（每日一次，2.5毫克）对20例患者（10例复发性钙肾结石患者和10例原发性高血压患者）尿液成分的影响，并与20例对照者进行了比较。吲达帕胺在每位患者中均吸收良好（稳态时平均血浆水平为111±41纳克/毫升），其降压作用在高血压患者中比在血压正常患者中更明显。它使18/20例患者的钙排泄量降低（治疗第7天平均下降：53%），并使20/20例患者的镁/钙比值升高（第7天平均升高：167%）。对钙和镁排泄的影响与强效利尿作用无关。在静脉注射钙负荷（0.375毫摩尔/千克体重）期间，6名正常受试者单次口服吲达帕胺后钙排泄减少，提示该药物具有直接的肾脏低钙尿作用。在有危险的肾脏钙流失的疾病中，吲达帕胺可能是噻嗪类利尿剂的替代药物，但需要进行长期研究。
